Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02470377 · ClinicalTrials.gov registry record · NA

Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome

A NA study of Mal de Debarquement Syndrome, sponsored by University of Minnesota.

Completed
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT02470377 is a NA study of Mal de Debarquement Syndrome that has completed, run by University of Minnesota. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02470377, a NA study of Mal de Debarquement Syndrome, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to determine whether external neuromodulation using repetitive transcranial magnetic stimulation (rTMS) can reduce the perception of self-motion that is experienced by individuals with mal de debarquement syndrome (MdDS). Mal de debarquement is translated as the "sickness of disembarkment," and refers to the chronic feeling of rocking dizziness that occurs after exposure to passive motion. Treatment for MdDS is limited and morbidity is high. The goal of the study is to determine whether rTMS can suppress the rocking dizziness of MdDS.

Interventions

  • DEVICE Transcranial Magnetic Stimulation

Study Locations (1)

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2015-08
Est. Completion 2017-07
Phase NA

Sponsor

University of Minnesota

966 total trials

What the Registry Record Tells You About NCT02470377

The ClinicalTrials.gov registry entry for NCT02470377 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mal de Debarquement Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Transcranial Magnetic Stimulation is the first listed.

NCT02470377 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT02470377 about?

NCT02470377 is a clinical study titled "Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome". The goal of this study is to determine whether external neuromodulation using repetitive transcranial magnetic stimulation (rTMS) can reduce the perception of self-motion that is experienced by individuals with mal de debarquement syndrome (MdDS). Mal de debarquement is translated as the "sickness o...

What is the current status of trial NCT02470377?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2015-08. Estimated completion is 2017-07.

What conditions does trial NCT02470377 study?

This clinical trial studies the following conditions: Mal de Debarquement Syndrome.

What interventions are being tested in trial NCT02470377?

The interventions under investigation include: Transcranial Magnetic Stimulation (DEVICE).

Who is sponsoring clinical trial NCT02470377?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02470377 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.